Vaccine makers raise concerns over US panel’s shift away from hepatitis B shots for newborns

The CDC Advisory Committee on Immunization Practices voted to drop its long-standing universal birth dose recommendation for hepatitis B, advising the birth dose only for infants of mothers who test positive; parents of infants with hepatitis B–negative mothers are now urged to consult providers on timing. Vaccine makers Merck and GSK voiced deep concern—Merck highlighted that the 1991 universal birth dose drove a 99% drop in acute pediatric cases and cited data showing prevention of more than 500,000 childhood infections and an estimated 90,100 deaths—while Merck and GSK shares slipped about 1% and Sanofi rose ~0.7% after the vote. The move, driven in part by committee members appointed by HHS Secretary Robert F. Kennedy Jr., raises public-health and regulatory uncertainty and could pressure vaccine makers and public health policy expectations.

Analysis

Market structure: The ACIP shift is a concentrated demand shock for the U.S. newborn hepatitis‑B birth‑dose segment; immediate winners are diagnostics/HBV‑screening providers and targeted prophylaxis (HBIG) suppliers, losers are manufacturers of single‑use birth‑dose vials used at delivery (Merck MRK and GSK). Pricing power for MRK/GSK in the U.S. birth‑dose channel falls; global pediatric series and adolescent catch‑up demand cushions revenue, so full-year U.S. vaccine volumes could decline ~20–50% over 12–24 months if uptake drops materially. Cross‑asset: expect modest short‑term equity downside and higher equity‑option IV for MRK/GSK, limited sovereign bond impact, and potential USD safe‑haven inflows if political/regulatory risk broadens.

Key Decisions for Investors

• Establish a 1.5% portfolio long in SNY and a 1.5% short in MRK as a pair over 3–6 months (target relative outperformance of 4–8%); stop-loss if the pair underperforms by 3% and trim/close at CDC formal adoption reversal or if MRK/GSK shares gap <‑5% on earnings.
• Buy a tactical MRK 3‑month put spread sized to 0.5% portfolio risk (e.g., 5%/12% OTM) to profit from headline-driven downside and IV expansion; enter only if CDC formally adopts the recommendation within 30 days or MRK stock drops >3% intraday on follow‑up news.
• Go long Quest Diagnostics (DGX) 1% portfolio weight over 6–12 months to capture higher maternal HBV screening and confirmatory testing demand; add on a pullback ≥5% or if state policies increase prenatal screening within 60 days.
• If MRK or GSK exposure >2% of portfolio, reduce that exposure by 25% within the next 10 trading days to limit political/regulatory tail‑risk; reinstate only after 60 days of stable CDC guidance or demonstrable public uptake metrics (birth‑dose coverage >80%).